S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought

Vaccine Stocks List

Compare vaccine stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Learn more about trading vaccine stocks.

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$80.00
$77.54
$61.44
$89.74
$99.68 B0.375.85 million shs3.38 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$101.49
+1.2%
$119.97
$98.43
$217.25
$38.63 B1.623.52 million shs2.86 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.36
-4.3%
$7.88
$5.61
$44.02
$694.78 M1.686.44 million shs6.41 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$173.85
+1.0%
$164.90
$150.11
$181.04
$451.83 B0.549.09 million shs45.91 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$36.04
+0.9%
$37.10
$34.65
$54.93
$203.48 B0.624.42 million shs16.61 million shs
Beginners Guide To Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%+1.68%+3.64%+2.07%+27.06%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-6.19%-16.37%-22.09%-40.71%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-8.68%-15.21%-9.25%-82.25%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+2.85%+8.74%+8.96%+5.17%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+2.91%-0.77%-3.01%-28.08%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
3.3666 of 5 stars
3.33.04.24.12.62.53.8
Moderna, Inc. stock logo
MRNA
Moderna
2.711 of 5 stars
4.12.00.04.62.43.31.3
Novavax, Inc. stock logo
NVAX
Novavax
2.1064 of 5 stars
3.11.00.04.73.11.70.6
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.6094 of 5 stars
2.23.03.33.93.12.51.9
Pfizer Inc. stock logo
PFE
Pfizer
3.3597 of 5 stars
4.25.05.04.62.41.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.53
Moderate Buy$90.5013.13% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.17
Hold$156.0753.78% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.20
Hold$33.00348.37% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.33
Hold$171.80-1.18% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.31
Hold$46.3528.62% Upside

Current Analyst Ratings

Latest Vaccine Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2023
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
8/9/2023
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$15.00
8/4/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $88.00
8/4/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$83.00 ➝ $84.00
8/4/2023
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$128.00 ➝ $123.00
8/4/2023
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$200.00 ➝ $190.00
8/4/2023
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$275.00 ➝ $175.00
8/4/2023
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$175.00 ➝ $150.00
8/4/2023
Moderna, Inc. stock logo
MRNA
Moderna
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$145.00 ➝ $125.00
8/4/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$167.00 ➝ $170.00
8/3/2023
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$200.00 ➝ $125.00
(Data available from 8/14/2020 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.28B3.65$8.98 per share8.91$16.93 per share4.73
Moderna, Inc. stock logo
MRNA
Moderna
$10.52B3.67$22.76 per share4.46$44.53 per share2.28
Novavax, Inc. stock logo
NVAX
Novavax
$1.98B0.35N/AN/A($7.99) per share-0.92
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.94B4.76$13.01 per share13.36$29.40 per share5.91
Pfizer Inc. stock logo
PFE
Pfizer
$100.33B2.03$7.62 per share4.73$17.59 per share2.05

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$4.59B$4.3518.3911.000.9020.03%37.53%12.66%10/26/2023 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
$8.36B$2.7137.45N/AN/A11.33%6.62%4.93%11/2/2023 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$657.94M-$7.26N/AN/AN/A-36.73%N/A-30.27%11/14/2023 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$17.94B$4.9435.1915.402.9213.35%36.72%14.62%10/17/2023 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$31.37B$3.769.5911.161.2127.55%28.36%13.66%11/7/2023 (Estimated)

Latest Vaccine Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/20236/30/2023
Novavax, Inc. stock logo
NVAX
Novavax
-$1.24$0.58+$1.82$0.58$264.16 million$424.40 million      
8/3/2023Q2 23
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.64$1.34-$0.30$1.85$6.45 billion$6.60 billion    
8/3/2023Q2 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$3.84-$3.62+$0.22-$3.62$307.67 million$344.00 million    
8/1/20236/30/2023
Pfizer Inc. stock logo
PFE
Pfizer
$0.57$0.67+$0.10$0.93$13.36 billion$12.73 billion    
7/20/20236/30/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.62$2.80+$0.18$3.64$24.63 billion$25.53 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.003.75%+5.03%68.97%8 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.762.74%+5.87%96.36%62 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.644.55%+3.31%43.62%12 Years

Latest Vaccine Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/3/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.753.97%9/14/20239/15/20239/28/2023
7/20/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Quarterly$1.192.83%8/25/20238/28/20239/7/2023
6/22/2023
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.414.22%7/27/20237/28/20239/5/2023
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.07
1.02
0.88
Moderna, Inc. stock logo
MRNA
Moderna
0.05
3.39
3.16
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.71
0.49
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.12
0.88
Pfizer Inc. stock logo
PFE
Pfizer
0.62
2.12
1.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
81.59%
Moderna, Inc. stock logo
MRNA
Moderna
70.44%
Novavax, Inc. stock logo
NVAX
Novavax
68.18%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
67.57%
Pfizer Inc. stock logo
PFE
Pfizer
67.80%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%
Novavax, Inc. stock logo
NVAX
Novavax
0.90%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.20%
Pfizer Inc. stock logo
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.25 billion1.24 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900380.59 million320.84 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,99294.40 million93.55 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
155,8002.60 billion2.59 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.65 billion5.64 billionOptionable

Vaccine Stocks Headlines

SourceHeadline
New Covid Strain Arrives as Vaccine Makers Gear UpNew Covid Strain Arrives as Vaccine Makers Gear Up
finance.yahoo.com - August 13 at 2:28 PM
Does Pfizer Stock Belong in a Dividend Portfolio?Does Pfizer Stock Belong in a Dividend Portfolio?
msn.com - August 12 at 11:17 PM
2 High-Yield Dividend Stocks That Could Be Incredible Bargains2 High-Yield Dividend Stocks That Could Be Incredible Bargains
finance.yahoo.com - August 12 at 8:12 AM
Meiji Yasuda Asset Management Co Ltd. Trims Holdings in Pfizer Inc. (NYSE:PFE)Meiji Yasuda Asset Management Co Ltd. Trims Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - August 11 at 8:12 PM
Pfizers Unexpected Strength: Bullish Case Emerges Amid New Covid-19 WavePfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave
seekingalpha.com - August 11 at 3:14 PM
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul (PFE)3 Pharmaceutical Stocks to Buy and Hold for the Long Haul (PFE)
marketbeat.com - August 11 at 9:31 AM
Pfizer Unusual Options Activity For August 10Pfizer Unusual Options Activity For August 10
benzinga.com - August 11 at 12:51 AM
UPDATE 1-Germanys Evonik second-quarter core profit slumps 38%UPDATE 1-Germany's Evonik second-quarter core profit slumps 38%
finance.yahoo.com - August 10 at 9:35 AM
Endo sues Zydus to block generic version of Pfizers ChantixEndo sues Zydus to block generic version of Pfizer's Chantix
reuters.com - August 9 at 7:18 PM
Pfizers Profits Plunge 77%: Is the Dividend Still Safe?Pfizer's Profits Plunge 77%: Is the Dividend Still Safe?
finance.yahoo.com - August 9 at 2:17 PM
20 Cities with the Cheapest Weed in the World20 Cities with the Cheapest Weed in the World
finance.yahoo.com - August 8 at 6:14 PM
Q2 2023 ICU Medical Inc Earnings CallQ2 2023 ICU Medical Inc Earnings Call
finance.yahoo.com - August 8 at 8:13 AM
FY2024 Earnings Estimate for Pfizer Inc. Issued By Cantor Fitzgerald (NYSE:PFE)FY2024 Earnings Estimate for Pfizer Inc. Issued By Cantor Fitzgerald (NYSE:PFE)
americanbankingnews.com - August 8 at 5:07 AM
Pfizer Offers Good ValuePfizer Offers Good Value
gurufocus.com - August 7 at 6:11 PM
BMO Capital Remains a Buy on Pfizer (PFE)BMO Capital Remains a Buy on Pfizer (PFE)
markets.businessinsider.com - August 7 at 1:43 PM
Pfizer (NYSE:PFE) Seeks Greener Pastures to Boost SalesPfizer (NYSE:PFE) Seeks Greener Pastures to Boost Sales
msn.com - August 7 at 1:43 PM
BioNTech Stock Drops. What’s Behind Today’s Fall.BioNTech Stock Drops. What’s Behind Today’s Fall.
finance.yahoo.com - August 7 at 1:43 PM
Morningstar: 8 Stocks for Long-Term InvestorsMorningstar: 8 Stocks for Long-Term Investors
finance.yahoo.com - August 7 at 1:43 PM
FY2024 Earnings Estimate for Pfizer Inc. (NYSE:PFE) Issued By Cantor FitzgeraldFY2024 Earnings Estimate for Pfizer Inc. (NYSE:PFE) Issued By Cantor Fitzgerald
marketbeat.com - August 7 at 8:27 AM
Morningstars 8 Favorite Stocks for Investors Looking for Long-Term OpportunitiesMorningstar's 8 Favorite Stocks for Investors Looking for 'Long-Term Opportunities'
finance.yahoo.com - August 6 at 4:47 PM
Pfizers Covid Boost Crashes to EarthPfizer's Covid Boost Crashes to Earth
wsj.com - August 6 at 11:07 AM
Want $5,000 of Super-Safe Annual Income? Invest $91,400 in These 3 High-Yield Dividend StocksWant $5,000 of Super-Safe Annual Income? Invest $91,400 in These 3 High-Yield Dividend Stocks
finance.yahoo.com - August 6 at 9:25 AM
Pfizer’s Covid Boost Crashes to EarthPfizer’s Covid Boost Crashes to Earth
finance.yahoo.com - August 6 at 9:25 AM
Pfizer Inc. to Post Q1 2024 Earnings of $0.98 Per Share, Leerink Partnrs Forecasts (NYSE:PFE)Pfizer Inc. to Post Q1 2024 Earnings of $0.98 Per Share, Leerink Partnrs Forecasts (NYSE:PFE)
americanbankingnews.com - August 6 at 2:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Recent vaccines Headlines

More vaccines Headlines

Key Points

  • A high demand for vaccines and a growing global economy is increasing international demand for vaccines. 
  • The vaccine industry is rife with risks, including the risk of failed clinical trials and regulatory risks. 
  • Learn more about multiple methods to invest in medical developments and what might have been the best stocks to buy during coronavirus. 

While you may not be able to invest in a specific vaccine, there are plenty of ways for investors to put money into companies that research and manufacture vaccines. Vaccine stocks have spiked in popularity among investors following the onset of the COVID-19 pandemic. Many pharmaceutical and biotech companies are involved in vaccine development; some are publicly traded on stock exchanges. By investing in these companies, you can benefit from their success in developing and selling vaccines.

Ready to learn more about pharmaceutical and COVID vaccine stocks? Read on to learn more about multiple methods to invest in medical developments and what might have been the best stocks to buy during coronavirus

Overview of Vaccine Stocks

A vaccine stock is associated with a company that produces vaccines, researches new vaccine technologies and provides vaccine transportation services. Vaccine development typically involves extensive research and clinical trials, which federal governments may fund partially. 

Once regulatory agencies have approved a vaccine, it can be marketed and sold to healthcare providers and patients. Exploring a healthcare stock list will expose you to some of the largest players in the vaccine industry. 

Why Invest in Vaccine Stocks?

Vaccines are crucial tools used to treat and prevent hundreds of fatal illnesses and conditions. Investing in a pharmaceutical or biotech company involved in drug and gene therapy development can produce strong returns if the company passes successful trials. 

The demand for vaccines will continue to grow in the coming years as the global population continues to age. It can provide long-term growth potential for vaccine stocks, many of which also invest heavily in other sectors of the healthcare sphere. It may also offer diversification for your portfolio within the healthcare industry. 

how to invest in vaccine stocks

3 Ways to Invest in Vaccines 

While you can no longer invest in a COVID-19 stock before the vaccination's development, many other healthcare-centered stocks focus on vaccine development. 

Pharmaceutical Stocks

The easiest way to invest in companies researching vaccines is to invest in one of the many pharmaceutical companies devoting a portion of research and development funds to new vaccines. Large pharmaceutical companies such as Pfizer Inc. (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ) have been developing vaccines for decades. 

JNJMajor pharmaceutical providers like Johnson & Johnson have rebounded since the onset of the COVID-19 pandemic. 

Major pharmaceutical providers have extensive research and development budgets, allowing them to simultaneously work on vaccines for various incurable illnesses. Major pharmaceutical companies may also invest heavily in clinical trials, regulatory compliance, and marketing efforts to get their products approved and reach patients needing them. 

Pharmaceutical companies may partner with the federal government to streamline or improve vaccine development. For example, the United States spent more than $18 billion on COVID-19 vaccine research and development. You can find a list of the best pharmaceutical stocks on MarketBeat

Biotech Companies

Biotech companies use advanced biotechnology techniques to create vaccines, which can involve genetically engineering viruses or bacteria. They may invest in research and development like pharmaceutical companies but devote most research to novel medical solutions using human genomes. Major companies in the biotech sphere include Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX)

Biotech stocks became popular among stock traders looking to invest in a COVID vaccine, as the virus seems unresponsive to known vaccine creation methods. For example, Moderna shot to the top of the list of best stocks to buy during the coronavirus, thanks to its breakthrough COVID-19 vaccine. Moderna's vaccine is based on mRNA (messenger RNA) technology, which introduces a small piece of genetic material called mRNA into the body. This advancement could not have been possible without biotech companies' capacity to isolate RNA from a sample of human DNA. 

While the cure for COVID-19 is no longer biotech companies' primary area of research, many continue to explore gene therapies to develop new treatment strategies. Future research areas in the biotech sphere include developing gene therapies for neurological disorders and gene editing projects. You can learn more about how to invest in biotech stocks and possibly COVID stocks. 

Vaccine Supply Chain Companies

Vaccinations often use living compounds or severely weakened forms of diseases to create vaccines. This creates a supply chain problem regarding product distribution, as vaccines usually need to be kept in a controlled environment, including at a specific temperature during transportation. 

Vaccine supplies specialize in transporting and storing temperature-sensitive products, including vaccines. These companies use specialized refrigerated trucks, containers and warehouses to ensure that vaccines stay at the proper temperature during transportation and storage. While they may not seem as important as pharmaceutical and biotech companies, vaccine supply chain providers play a crucial role in the healthcare system. Examples of vaccine supply chain companies include AmerisourceBergen Corp. (NYSE: ABC) and Cryoport Inc. (NASDAQ: CYRX).

How to Invest in Vaccine Stocks

If you've invested in the stock market before, you'll find that buying and selling vaccine stock is the same as buying any other type of tradable asset. If you're unfamiliar with investing, take the following steps to start your foray into the healthcare system and vaccines stock. 

Step 1: Explore healthcare stocks.

As we mentioned above, multiple types of companies are involved in manufacturing and distributing vaccines. Start by exploring healthcare stocks in the industry, and research each company's recent profit statements and analyst ratings to create a list of viable stock investments. To begin your search, you can explore some of the top medical stocks on MarketBeat

Another way to invest in the vaccine industry is to invest in exchange-traded funds (ETFs) or mutual funds focusing on the healthcare sector. These funds typically invest in a diversified portfolio of companies in the healthcare industry, including vaccine manufacturers. This approach can offer investors greater diversification and lower risk than investing in individual stocks. Research multiple investment vehicles and decide how you want to invest before proceeding. 

Step 2: Fund your brokerage account.

Before investing in assets from your healthcare stocks list, you must open a brokerage account. A brokerage account is a type of investment account that you can use to buy and sell shares of stocks by placing instructions with your broker. 

Research different brokerage firms to find the one that suits your investment goals and preferences. Consider factors such as fees, minimum balance requirements, investment options and customer service when selecting an account. Once you find a broker that suits your needs, apply for an account using your personal information. 

After submitting your application, the brokerage firm will typically verify your information and may require additional documentation. Once your account is approved, you can fund it by transferring money from your bank account. Some brokers may also allow you to invest in stocks using a credit or debit card. 

Step 3: Buy the stock and manage your investment.

Once you fund your account, you can start investing by buying and selling stocks, ETFs and other assets your broker offers. Select the asset that you're interested in purchasing, and place an order through your brokerage account. Most brokers offer various order types, allowing you to control the price you pay per share and when your order executes.

If your broker can complete the order according to your instructions, you'll see your shares in your brokerage account. Monitor your assets' performance and how they change in value to manage your investment. 

Pros and Cons of Investing in Vaccine Stocks

Like any investment, before investing in vaccine stocks, there are potential benefits and risks. 

Pros

The benefits of investing in vaccine stocks include:

  • High demand: Vaccines are in high demand globally, and the vaccine market should grow in the coming years. Vaccine stocks may be a good investment opportunity for those seeking long-term growth potential.
  • Positive growth prospects: Many vaccine manufacturers have seen significant growth in their stock prices over the past year after being classified as COVID-19 stocks. For example, Moderna's stock price spiked more than 200% during the height of the COVID-19 pandemic. Investing in vaccine stocks now can result in a significant profit if the company makes a successful vaccination debut. 
  • Potential for government support: Governments worldwide invest heavily in vaccine development and distribution. This funding can boost vaccine manufacturers' bottom lines, making them more attractive to investors.

Cons

On the flip side, the cons include:

  • Regulatory risk: Vaccine development and manufacturing are subject to stringent regulations from government agencies, which can lead to delays and increased costs. Regulatory risks can also increase if there are concerns about the safety or efficacy of vaccines produced by the company you invest in.
  • Possibility of failure in clinical trials: Vaccine development involves extensive clinical trials that can take several years to complete. These trials are costly and can fail to achieve their objective. This may lead to financial losses for investors.

Future of Vaccine Investing 

The COVID-19 pandemic has highlighted the importance of vaccine development and distribution. The demand for COVID-19 vaccines is likely to continue for the foreseeable future, and there may be additional opportunities for vaccine manufacturers to develop booster shots or new vaccine variants. Technological advancements uncovered during the investigation of COVID-19, such as the use of mRNA in vaccine development, may lead to breakthroughs that can benefit investors. 

Demand for vaccines should increase in the future due to increased globalization. The international demand for vaccines may create additional supply chain issues, especially when transporting vaccines across borders. Investors interested in diversifying their portfolio may want to explore international pharmaceutical stocks or supply chain management companies for future investment potential. 

Investing in Vaccine Stocks

While the vaccine industry provides plenty of opportunities for investors, its also a highly competitive and often risky sector for investors. A vaccine can only be distributed once proven safe and effective in a series of government-overseen trials. This can delay investor returns or even lead to losses if trials are unsuccessful. Be sure to explore all of the best biotech stocks on MarketBeat and the largest pharmaceutical companies in the world before choosing where to place your funds. 

FAQs

Look at some frequently asked questions before you get started on your own vaccine investing journey.

What companies make the COVID vaccine?

Several companies have developed COVID-19 vaccines, including Pfizer-BioNTech, Moderna and Johnson & Johnson. These companies have received use authorization from regulatory agencies in various countries, including the United States and most countries in the European Union. Each vaccine uses different technology to trigger an immune response against the virus.

How much money did the U.S. invest in COVID vaccine?

To date, the government of the United States has invested more than $30 billion in a COVID-19 vaccine. This total cost includes research, development, trials and vaccine distribution.  

What does Novavax make?

Novavax is a biotechnology company that develops vaccines for infectious diseases. It is best known for its COVID-19 vaccine, which uses a protein-based technology to trigger an immune response. In addition to a COVID-19 vaccine, Novavax is also developing vaccines for other infectious diseases, including influenza and Ebola.

Sarah Horvath

About Sarah Horvath

Contributing Author: Retail, Healthcare, and Real Estate stocks

Sarah Horvath is an accomplished financial writer focused on the topics of investing, insurance, and mortgage options. You can find her work on major finance outlets, including Forbes, Benzinga, and through companies like Nationwide and Vanguard. She prides herself on making complicated financial topics easier to understand. When not writing, she spends her time with her fiancé and beloved parrot.
Contact Sarah Horvath via email at horvath.sarah17@gmail.com.

My Account -